
Yüksel Ürün/X
Apr 8, 2025, 03:09
Yüksel Ürün: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers – where immunotherapy usually fails.
Neoantigen recognition may be the key.”
“Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial”
Authors:Frank J. Lowery et al.
Aaron J. Dinerman
Aarushi Bhasin
Abraham A. Hakim
Alakesh Bera
Alexandra M. Gustafson
Billel Gasmi
cancer
Chuong D. Hoang
Courtney D. Seavey
Frank J. Lowery
Hyunmi K. Halas
Ian S. Goldlust
James C. Yang
Jared J. Gartner
Jonathan M. Hernandez
Juliette G. Rault-Wang
Kyle J. Hitscherich
Lior Levy
Lisa M. Kenney
Lori S. McIntyre
Maria R. Parkhurst
Mei Li M. Kwong
Michelle M. Langhan
Nicholas D. Klemen
Nivedita M. Ratnam
OncoDaily
Oncology
Paul F. Robbins
Satyajit Ray
Sivasish Sindiri
Sri Krishna
Stephanie L. Goff
Steven A. Rosenberg
Thomas E. Shelton
Todd D. Prickett
Victoria Dulemba
Yüksel Ürün
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 18:57
Apr 15, 2025, 18:26
Apr 15, 2025, 17:49
Apr 15, 2025, 17:41